Scientist.com and PhenoVista Launch World’s First Digital Storefront Offering Research Services for the Biotech Industry
Scientist.com, the pharma industry’s leading research marketplace, and PhenoVista, a life sciences services company developing and implementing multiplexed, high content imaging-based phenotypic assays for target validation, lead optimization, and mechanism of action studies, have launched the biotech industry’s first digital eShop for exploring and purchasing phenotypic studies.
The digital storefront makes it easy for scientists to design complex research projects, get feedback from PhenoVista’s experts, determine pricing, and then purchase and manage projects. What previously could require hours of face-to-face meetings or video calls can now be accomplished online in much less time. The Shopify-like virtual store was created by Scientist.com and is designed to make it as easy to purchase complex assay services as it is to buy products and reagents.
“Today, almost half of the $240B spent annually on drug research is performed by companies like PhenoVista that offer highly technical and specialized custom assay services,” said Kevin Lustig, PhD, CEO and Founder at Scientist.com. “With the launch of PhenoVista’s online store, researchers get more immediate access to their services and expertise, allowing them to accelerate crucial experiments and benefit from the use of data-rich phenotypic studies.”
There are significant advantages offered by high-plex phenotypic studies across the entire R&D workflow as compared to conventional, low-plex in vitro assays.
“High-stakes decision making is at the heart of R&D, and uncertainty about targets, mechanisms of action, and whether to advance or abandon candidate compounds is the norm,” said James G. Evans, CEO and Founder of PhenoVista. “With expertise in high-content imaging-based phenotypic studies, we deliver the biological insights and high-quality data needed to inform and de-risk these decisions. We are excited to leverage the marketplace experience established by Scientist.com to create our virtual storefront and bring added convenience to researchers in the biotech industry.”
The virtual storefront can be accessed at https://store.phenovista.com/.
About Scientist.com
Scientist.com is a privately held San Diego-based company on a mission to make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace that helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. Through Scientist.com, scientists communicate directly with research experts at over 4,000 global laboratories to design and execute complex research experiments. Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram.
About PhenoVista
Founded in 2014, PhenoVista is a leader in the development and implementation of multiplexed, high content imaging-based phenotypic assays for biopharmaceutical clients. These assays deliver the high-quality, quantitative data needed to inform and de-risk critical R&D decisions with greater confidence. Clients gain access to novel insights related to the complex biology underlying target validation, therapeutic delivery, efficacy and safety, cytotoxicity, and mechanisms of action, increasing the likelihood of success of first-in-class drug candidates. To learn more, visit our website www.phenovista.com or see us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214355636/en/
Contact information
PhenoVista
Christine Quern
cq@christinequern.com
617-650-8497
Scientist.com
Sean Preci
marketing@scientist.com
877-644-3044
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release
Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release
Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor
Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release
Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom